Objective-Aberrant proliferation of smooth muscle cells (SMC) in response to injury induces pathological vascular remodeling during atherosclerosis and neointima formation. Telomerase is rate limiting for tissue renewal and cell replication; however, the physiological role of telomerase in vascular diseases remains to be determined. The goal of the present study was to determine whether telomerase reverse transcriptase (TERT) affects proliferative vascular remodeling and to define the molecular mechanism by which TERT supports SMC proliferation. Approach and Results-We first demonstrate high levels of TERT expression in replicating SMC of atherosclerotic and neointimal lesions. Using a model of guidewire-induced arterial injury, we demonstrate decreased neointima formation in TERT-deficient mice. Studies in SMC isolated from TERT-deficient and TERT overexpressing mice with normal telomere length established that TERT is necessary and sufficient for cell proliferation. TERT deficiency did not induce a senescent phenotype but resulted in G1 arrest albeit hyperphosphorylation of the retinoblastoma protein. This proliferative arrest was associated with stable silencing of the E2F1-dependent S-phase gene expression program and not reversed by ectopic overexpression of E2F1. Finally, chromatin immunoprecipitation and accessibility assays revealed that TERT is recruited to E2F1 target sites and promotes chromatin accessibility for E2F1 by facilitating the acquisition of permissive histone modifications. cultured cells, TERT is induced in both activated macrophages and proliferating SMC. 14, 17 In SMC, the transient increase in TERT abundance in response to growth factor stimulation serves a mitogenic role because inhibition of TERT by oligonucleotide or pharmacological targeting inhibits SMC proliferation. 15, [17] [18] [19] [20] Furthermore, acute telomerase downregulation using TERT antisense RNA decreases proliferation of SMC isolated from genetically hypertensive rats. 21 Although recent genetic experiments established that the mitogenic activity of TERT requires neither telomere extension nor the catalytic activity, 5-8 the molecular mechanisms by which TERT supports cellular proliferation remain elusive.
T elomerase has been implicated in multiple developmental processes, including cell activation, differentiation, proliferation, and apoptosis. 1 The catalytic activity of telomerase maintains telomeres, hexanucleotide DNA-protein complexes that protect the ends of chromosomes, and is rate-limiting for tissue renewal. 2 Because most somatic cells repress the telomerase reverse transcriptase (TERT) catalytic core, telomeres shorten progressively during tissue renewal, ultimately limiting lifespan. 3 In addition to the extension of telomeres, mounting evidence suggests that TERT exhibits a direct regulatory role in the activation of gene expression without apparent involvement of its well-established function in telomere homeostasis. 4 Early profiling experiments first documented that TERT induces differential gene expression. 5 More recent support for a noncanonical activity of TERT derives from the observation that TERT induces cell proliferation independently of its catalytic activity and function to elongate telomeres. [5] [6] [7] [8] [9] Although the mechanisms underlying this noncanonical, mitogenic function of TERT remain elusive, TERT has been demonstrated to activate specific transcriptional programs and associates with chromatin at locations distant to telomeres, indicating a possible function of TERT in the epigenetic control of gene expression. 10, 11 Aberrant cell proliferation constitutes an important mechanism underlying proliferative vascular remodeling during atherosclerosis and neointima formation. 12 Although telomerase is recognized as one of the most ancestral proteins in the control of mammalian cell proliferation, it remains to be investigated whether TERT causally contributes to these cardiovascular diseases. TERT expression is low in quiescent smooth muscle cell (SMC) of the normal vasculature, 13, 14 but increased during neointima formation and atherosclerosis development. [14] [15] [16] In cultured cells, TERT is induced in both activated macrophages and proliferating SMC. 14, 17 In SMC, the transient increase in TERT abundance in response to growth factor stimulation serves a mitogenic role because inhibition of TERT by oligonucleotide or pharmacological targeting inhibits SMC proliferation. 15, [17] [18] [19] [20] Furthermore, acute telomerase downregulation using TERT antisense RNA decreases proliferation of SMC isolated from genetically hypertensive rats. 21 Although recent genetic experiments established that the mitogenic activity of TERT requires neither telomere extension nor the catalytic activity, [5] [6] [7] [8] the molecular mechanisms by which TERT supports cellular proliferation remain elusive.
In this study, we used a genetic model of TERT deficiency to investigate the transcriptional mechanisms underlying the mitogenic activity of TERT during proliferative vascular remodeling. Our studies reveal that TERT deletion prevents neointima formation and SMC proliferation by inducing a silenced chromatin environment at S phase gene promoters.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

TERT Is Expressed in Replicating Neointimal Smooth Muscle Cells
TERT protein expression was first analyzed in neointimal SMC of human coronary artery atherosclerotic lesions from hearts explanted during cardiac transplantation. Although TERT expression is considered negligible in normal arteries, 13, 14 we confirmed abundant TERT expression in the SMCrich neointimal region of the fibroatheroma ( Figure 1A) . Furthermore, confocal microscopy confirmed that TERT expression colocalizes with proliferating cell nuclear antigen (PCNA), a cofactor of DNA polymerase required for replication ( Figure 1B) . Similarly, TERT was highly expressed in replicating SMC during the proliferative response after vascular injury of the mouse femoral artery ( Figure 1C ). Therefore, this upregulation of TERT expression may indicate an important role in vascular remodeling underlying neointima formation.
TERT Is Required for Smooth Muscle Cell Proliferation and Neointima Formation
Inhibition of TERT has previously been shown to inhibit SMC proliferation. [17] [18] [19] Using siRNA-mediated TERT knockdown and adenoviral-mediated overexpression of TERT ( Figure IA through IC in the online-only Data Supplement), we corroborated that TERT is both necessary and sufficient for SMC proliferation (Figure 2A and 2B). To advance these studies to in vivo models, we next isolated primary aortic SMC from TERT-deficient and TERT overexpressing mice. 22 Consistent with the well-described phenotype, [22] [23] [24] [25] the first generation G1TERT −/− progeny from heterozygote founder mice exhibits normal telomere length ( Figure II in the onlineonly Data Supplement) and none of the phenotypes associated with telomere attrition. However, homozygous intercrossing of G1TERT −/− mice results in progressive telomere loss in third generation G3TERT −/− mice ( Figure II in the online-only Data Supplement). To further complement this genetic TERT depletion model, we studied proliferation of SMC isolated from C57BL/6 mice overexpressing a murine TERT transgene under control of the ubiquitin C promoter (referred to as TERTtransgenic). 22 When exponentially growing aortic SMC from these mice were analyzed ( Figure 2C ), cells isolated from hemizygous TERTtransgenic mice displayed a marked growth advantage compared with their littermate controls (referred to as TERTwild-type). Conversely, SMC isolated from G1TERT −/− mice exhibited a complete growth arrest compared with G1TERT
+/+ cells. Interestingly, the growth arrest occurred to a similar extent in G1 and G3TERT −/− SMC, indicating that this mitogenic defect is primarily because of TERT deletion and does not require telomere attrition. To further corroborate that the mitogenic arrest is because of TERT deficiency, we overexpressed TERT in G1TERT −/− SMC, which rescued proliferation ( Figure 2D ). Based on these data and to investigate the regulation of SMC proliferation by TERT in vivo, we next analyzed the proliferative response underlying neointima formation in G1TERT −/− mice. As depicted in Figure 3A and 3B, neointima formation was significantly decreased in G1TERT −/− mice compared with their wild-type G1TERT +/+ littermates. Collectively, these results indicate that TERT deletion decreases SMC proliferation in vitro and during neointima formation in vivo.
TERT Deletion Induces Cell Cycle Arrest and Silences E2F1 Target Gene Expression
We next sought to identify the mechanisms responsible for the growth arrest of G1TERT −/− SMC. Using real-time polymerase chain reaction (PCR) for sensitive quantification of telomere lengths, we first confirmed that G1TERT −/− SMC did not display measurable evidence of telomere attrition ( Figure II in the online-only Data Supplement). Furthermore, TERT deficiency did not induce senescence-associated β-galactosidase staining or gene expression ( Figure IIIA and IIIB) . From these data, we inferred that the growth arrest induced by TERT deficiency was likely independent of the well-established function of TERT to extend telomeres and prevent cellular senescence. Therefore, we next analyzed DNA synthesis and cell cycle distribution. These studies revealed that TERT deficiency inhibited mitogeninduced DNA synthesis ( Figure 4A ) and arrested SMC in the G 0 /G 1 phase of the cell cycle to reduce S phase entry ( Figure 4B and 4C). This transition from G 1 → S phase is mediated through phosphorylation of the retinoblastoma protein (Rb). 26 However, TERT depletion did not result in decreased Rb phosphorylation but rather hyperphosphorylation ( Figure 4D and 4E Rb phosphorylation releases the transcription factor E2F1, which transactivates promoters required for S phase entry and ensuing DNA replication, including the bona fide E2F1 target genes cyclin A, PCNA, and minichromosome maintenance proteins. 27, 28 Although Rb was hyperphosphorylated in G1TERT-deficient cells, downstream expression of these 3 E2F1 target genes was silenced ( Figure 4F ). This differential S phase gene expression profile occurred in the absence of changes in E2F1 expression levels ( Figure IV in the onlineonly Data Supplement). Similarly, other activating E2F family members were not affected by deletion of the TERT locus ( Figure IIIB in the online-only Data Supplement). To further complement this finding, we used siRNA-mediated knockdown of TERT in primary human coronary artery SMC. As depicted in Figure 4G through 4I, the induction of minichromosome maintenance protein 7 (MCM7) mRNA and protein expression in response to mitogenic stimulation was attenuated in TERT-depleted SMC. Complementary data were obtained for the E2F1 target genes cyclin A and PCNA (data not shown).
TERT Is Recruited to Chromatin and Required for E2F1 Binding to Canonical Sites
The silencing of E2F1 target gene expression in TERT-deficient SMC indicated that TERT might facilitate E2F1-dependent transcription. To assess this possibility, we first confirmed that E2F1 and TERT physically associate in human coronary artery SMC ( Figure 5A ). However, to more directly test whether TERT is recruited to canonical E2F1 motifs, we performed chromatin immunoprecipitation assays using primer pairs that cover the E2F1 sites in the cyclin A, PCNA, and MCM7 promoters. As shown in Figure 5B , mitogenic stimulation of G1TERT +/+ SMC induced not only E2F1 binding to its target site in the MCM7 promoter but also a potent and inducible corecruitment of TERT. Further evaluation of the chromatin complex demonstrated that this recruitment of E2F1 and TERT was associated with increased acetylation of histone H3, a typical chromatin modification of gene activation. 29 To investigate whether TERT is required for E2F1 binding to chromatin and to validate the role of TERT in the regulation of E2F1-dependent transcription, we next analyzed whether TERT deficiency affects E2F1 recruitment to its response elements within the MCM7, cyclin A, and PCNA promoters. As depicted in Figure 5C , inducible TERT binding to E2F1 canonical sites in the MCM7 promoter was negligible in human coronary artery SMC depleted of TERT using a lentiviral approach ( Figure ID B, Adenoviral-mediated overexpression of TERT promotes SMC proliferation. Serum-deprived human coronary artery SMC were transduced for 24 hours with 100 plaque-forming units (PFU) of adenoviral constructs overexpressing GFP/TERT (Adx-TERT/GFP) or GFP (Adx-GFP) as control. After transduction, proliferation was analyzed after 48 hours by cell counting using a hematocytometer. Data are presented as mean±SEM relative to quiescent GFP-infected cells (*P<0.05 vs Adx-GFP). C, Proliferation of vascular SMC isolated from TERT overexpressing (TERTtransgenic), littermate wild-type (TERTwildtype), first generation G1TERT −/− , littermate wild-type G1TERT +/+ , and third generation G3TERT −/− mice (n=8 mice per group). Serum-deprived SMC were stimulated with FBS and counted at the indicated time points using a hemocytometer. Data are presented as mean±SEM (*P<0.05 vs the respective wild-type control mice). D, TERT overexpression rescues the mitogenic defect of TERT-deficient SMC. Murine SMC from G1TERT −/− or G1TERT +/+ mice were infected with 100 PFU of Adx-TERT/GFP or Adx-GFP. Forty-eight hours after transduction, proliferation was analyzed by cell counting using a hematocytometer. Values are fold increase relative to G1TERT +/+ transduced by Adx-GFP and presented as mean±SEM (#P<0.05 vs Adx-GFP, *P<0.05 vs G1TERT +/+ ).
online-only Data Supplement), confirming specificity of the chromatin immunoprecipitation assay. Comparable results were observed for the cyclin A and PCNA promoters (data not shown). As further shown in Figure 5D through 5F, this mitogen-induced E2F1 recruitment to the MCM7, cyclin A, and PCNA promoters was significantly reduced on TERT depletion. A complementary impairment of E2F1 binding to its target sites was observed in G1TERT −/− murine cells (data not shown). These studies confirm that TERT supports E2F1 binding to its target sites within promoters of genes required for entry into S phase of the cell cycle.
TERT Deficiency Decreases Chromatin Accessibility and Histone Acetylation
We next examined chromatin accessibility specifically at E2F1 binding sites using a chromatin accessibility by realtime PCR assay. 30 Briefly, this highly sensitive assay to quantify chromatin accessibility combines DNase hypersensitivity with specific restriction enzyme digestion followed by PCR amplification, thereby providing a quantitative chromatin accessibility assessment at a specific transcription factor binding site. Genomic DNA from G1TERT −/− and G1TERT +/+ SMC was subjected to DNase I, meningococcal nuclease, and Cac8I restriction enzyme digestion followed by realtime PCR using primers encompassing the E2F1 motif in the MCM7 promoter ( Figure 6A ). The restriction enzyme Cac8I specifically cleaves the E2F1 motif TTTCGCGC, and accessible euchromatin will not be amplified by PCR because the primers cannot hybridize to the E2F1 site because of cleavage by the restriction enzyme. As shown in Figure 6B , TERT deficiency was associated with significantly reduced chromatin accessibility at the E2F1 site relative to G1TERT +/+ SMC. Because our data established that TERT occupancy of E2F1 sites is associated with the enrichment of histone H3 acetylation, we further analyzed whether TERT deficiency modulates the recruitment of permissive histone acetylation at E2F1 sites. As shown in Figure 6C , fetal bovine serum stimulation of human coronary artery SMC resulted in a profound increase in lysine 9 histone H3 acetylation of the E2F1 response elements within the MCM7 promoters. In contrast, this inducible histone acetylation was completely abolished in human coronary artery SMC transduced with TERT shRNA lentivirus. Similarly, mitogen-induced lysine 9 histone H3 acetylation was reduced at the protein level in G1TERT −/− SMC ( Figure 6D and 6E), a finding that may at least in part contribute to the silenced chromatin state at E2F1 sites in TERT-deficient cells. Considering that the p300/CREB-binding protein (CBP) coactivator family confers histone acetyltransferase activity 31 that is required for E2F1 activation of its S phase target genes, 32 we investigated whether CBP contributes to histone H3 acetylation during TERT-dependent E2F1 recruitment. A direct TERT-CBP interaction was first confirmed by immunoprecipitation ( Figure 6F ). Furthermore, mitogen-induced CBP recruitment to E2F1 target chromatin within the MCM7 promoter was confirmed by chromatin immunoprecipitation. In contrast, inducible CBP recruitment was markedly impaired on TERT deletion ( Figure 6G ). Decreased H3 acetylation and altered CBP recruitment on TERT depletion were also observed at the cyclin A and PCNA (data not shown). These findings suggest that TERT facilitates CBP recruitment and subsequent Histone H3 acetylation to disrupt repressive chromatin at E2F1 target chromatin.
To finally corroborate decreased chromatin accessibility as a possible mechanism underlying silencing of E2F1 target genes, we overexpressed E2F1 in G1TERT −/− SMC. A silenced chromatin state accompanying TERT deficiency should produce a permanent insensitivity to E2F1-dependent proliferation because E2F1 would be unable to access its consensus sites. As depicted in Figure 6H through 6J, adenoviralmediated transduction of E2F1 ( Figure VI in the online-only Data Supplement) in SMC wild-type for the TERT locus increased expression of its target gene MCM7 expression and the ensuing cell proliferation and DNA synthesis. In contrast, this activity of ectopic E2F1 to induce target gene transcription and cell proliferation was altered in TERT-deficient SMC. Collectively, these experiments identify TERT as a component of the chromatin complex at E2F1 sites and establish a previously unrecognized role for TERT to activate E2F1-dependent gene promoters through chromatin modulation.
Discussion
Altered SMC function constitutes a pivotal component of pathological vascular remodeling and neointima formation. 12, 33 In the present study, we illustrate a previously unrecognized mechanism that supports the mitogenic phenotype of SMC. The inducible expression of TERT in proliferating SMC during vascular remodeling and the requirement for SMC proliferation in vitro and neointima formation in vivo establish an important role for TERT in vascular biology. TERT is required for the activation of an S phase gene expression program, associates with chromatin at E2F1 consensus sites, and facilitates the acquisition of a permissive chromatin environment through CBP-mediated histone acetylation. Collectively, these experiments support a novel role for TERT in the epigenetic control of SMC proliferation.
Although expression of the catalytic subunit of telomerase TERT is considered to be negligible in the normal vasculature, 13, 14 we observed that TERT is induced in proliferating SMC during the neointimal remodeling process, resulting from atherosclerosis formation or vascular injury. Using loss and gain-of-function approaches combined with genetic TERT modulation in mice, our data demonstrate a causal relationship between TERT expression and the mitogenic response. Similarly, prior studies using oligonucleotide or pharmacological targeting of TERT documented decreased SMC proliferation. [17] [18] [19] To extend these observations, we studied SMC proliferation in primary cells isolated from G1TERT-deficient mice in vitro and neointima formation in vivo in mice deficient for the TERT locus. This murine model has been widely used to exploit telomereindependent functions of TERT in G1TERT −/− mice with normal telomere lengths, as well as phenotypes that occur as a result of progressive telomere attrition in third generation G3TERT −/− mice. 18, [34] [35] [36] [37] Conversely, constitutive expression of TERT in transgenic mice does not elongate telomeres 22 because TERT only elongates critically short telomeres. 38, 39 Therefore, this transgenic model provides another means to study TERT activities that occur independently of its function to extend telomeres. [6] [7] [8] [9] In our experiments, TERT deficiency in the presence of normal telomere length in G1TERT −/− mice induced growth arrest of SMC and reduced neointima formation. In contrast, TERT overexpression in SMC isolated from transgenic mice elicited a clear growth advantage. From these observations, we infer that the SMC growth arrest induced by TERT deficiency does not depend on telomere attrition but rather on TERT function. Consistent with this notion is the accumulating evidence that TERT induces, for example, stem cell and cancer proliferation through telomere-independent mechanisms that do not require the catalytic activity. [6] [7] [8] [9] [10] Furthermore, proliferating cancer cells express splice variants deficient in catalytic activity, and expression of these variants in telomerase-negative cells induces cell proliferation, 40 pointing to a novel noncanonical function of TERT in the regulation of cell proliferation.
G1TERT-deficient SMC did not display senescence-associated changes in their phenotype or gene expression, further supporting a telomere-independent mechanism of growth arrest. Instead, cell cycle analysis revealed that TERT deficiency induced a G1 → S phase arrest associated with decreased DNA synthesis. Similarly, acute knockdown of TERT in cancer cells induces cell cycle arrest without telomere shortening while TERT overexpression drives epithelial cells into S phase. 41, 42 In proliferating cells, phosphorylation of the Rb protein constitutes a critical first step for S phase entry, 26 which in turn releases its active transcriptional repression of E2F1. 26, 27 In TERT-deficient SMC, we observed hyperphosphorylation of Rb, which would be expected to release E2F1-dependent repression, induce target gene transcription, and facilitate S phase entry. Contrary to this assumption, mitotic E2F1 target genes required for DNA synthesis were silenced in TERT-deficient SMC, albeit increased Rb phosphorylation. This unanticipated requirement of TERT for E2F1-dependent transcription was neither the result of decreased E2F1 protein expression nor reversible by ectopic E2F1 overexpression, indicating a stable transcriptional silencing in response to TERT deletion that cannot be attributed to a lack of E2F1 availability. Alternatively, a model in which E2F1 is present but unable to gain access to cognate binding sites because of condensed chromatin in TERT-deficient SMC seems conceivable. The ensuing altered transcription of E2F1-dependent genes in turn may provide a positive feedback to mechanisms that are upstream of Rb and induce its phosphorylation to overcome the proliferative arrest. Consistent with this concept is our observation that altered expression of E2F1 target genes in TERT-deficient SMC is associated with decreased E2F1 binding to their respective consensus motifs. To our knowledge, these are the first data to demonstrate that E2F1-dependent activation of S phase genes requires TERT expression. These findings complement the more widely appreciated function of telomerase in maintaining telomere repeats and provide a molecular mechanism underlying the well-described, mitotic function of TERT.
Using chromatin immunoprecipitation assays, we demonstrate that TERT is recruited along with E2F1 to consensus sites within differentially regulated target genes. This inducible TERT occupancy of E2F1 sites is associated with the enrichment of CBP and permissive histone H3 acetylation on lysine 9. To confirm that TERT recruitment to E2F1 cognate elements is functionally important for the activation of chromatin, we probed for acetylated histone marks and chromatin accessibility. These studies revealed that TERT deletion decreases histone acetylation at E2F1 sites and reduces chromatin accessibility at the E2F1 site. Therefore, it is unlikely that the mechanism by which TERT activates E2F1-target promoters is through direct DNA binding but rather involves chromatin remodeling and facilitated recruitment of other chromatin-modifying enzymes. CBP supports histone acetyltransferase activity required for E2F1 binding. 32 Our observations support that the association of TERT with CBP facilitates its recruitment to chromatin and local histone acetylation, which releases repressive chromatin. This hypothesis is further supported by the recent finding that TERT regulates Wnt-dependent transcription in stem +/+ SMC stimulated with fetal bovine serum (FBS) for 10 hours. Cells were harvested for ChIP using antibodies against E2F1, TERT, or K9Ac-H3 (indicated as IP). Immunoprecipitation with respective nonimmune IgG served as control (indicated as IgG). Chromatin Input and nontemplate control (NTC) are depicted as additional controls. The precipitated chromatin was then amplified using primer pairs covering the E2F1 binding sites within the MCM7 promoter. C, Mitogen-induced TERT recruitment to E2F1 target chromatin. Forty-eight hours after lentiviral transduction with either nontargeting shRNA control (shCTL) particles or TERT shRNA (shTERT) particles, human coronary artery SMC were stimulated with FBS after 24 hour serum-free starvation and then harvested for ChIP assays. Chromatin immunoprecipitation was performed using antibody against TERT. Promoter binding was quantified by real-time PCR using primers covering E2F1 binding sites within the MCM7 promoter. Cycle threshold (C t ) values were normalized to C t values of input samples and presented as mean±SEM (#P<0.05 vs quiescent, *P<0.05 vs shCTL). D-F, TERT depletion abolishes mitogen-induced E2F1 binding to the promoters of MCM7 (D), cyclin A (E), and proliferating cell nuclear antigen (PCNA; F). Human coronary artery SMC were prepared as described in (C). ChIP was performed using anti-E2F1 antibody. Quantification of immunoprecipitated chromatin by real-time PCR using primers covering E2F1 binding sites within the promoter regions of MCM7, cyclin A, and PCNA. Data are presented as mean±SEM (#P<0.05 vs quiescent, *P<0.05 vs shCTL). 11 BRG1 constitutes the energy-providing subunit of multiple chromatin-modifying enzymatic complexes to disrupt the chromatin architecture of target promoters and recruit histone acetyltransferases, which represent critical steps for E2F1-induced promoter activation. 32 Considering our observation that TERT depletion decreased chromatin accessibility and histone acetylation at E2F1 sites, it is possible that TERT serves as a chaperone to facilitate the recruitment of BRG1 and histone acetyltransferase activity to E2F1 target sites. In addition to this mechanism, TERT has been reported to stabilize transcription factors through inhibition of ubiquitination. 43 However, because E2F1 protein levels were unaffected by TERT deletion, we would consider this mechanism unlikely to explain the chromatin remodeling of TERT-deficient SMC.
Based on our data, we conclude that transient re-expression of TERT during cell cycle progression provides a mechanism for the transcription of S phase cell cycle-regulatory genes. TERT is recruited to canonical E2F1 target genes and induces a permissive chromatin environment. In vivo, this mechanism is required for the proliferative response of SMC to induce neointima formation. Further investigation of this novel epigenetic function of TERT and characterization of TERT-regulated gene expression programs will likely yield new insights into how TERT functions as a regulator of cell proliferation. +/+ or G1TERT −/− mice were digested with Cac8I restriction enzyme and purified for chromatin accessibility by real-time polymerase chain reaction (ChART-PCR). Primers used for realtime PCR amplify sequences between nucleotides -346 and -176 in the MCM7 promoter, which encompass 2 E2F1 binding sites and 3 Cac8I restriction sites. Results were normalized against amplification of a control sequence upstream of the MCM7 promoter (nucleotides -620 to -513) with no Cac8I restriction sites. Data are presented as mean±SEM relative to uncut samples (*P<0.05 vs G1TERT +/+ ). C, TERT depletion abolishes mitogen-induced histone H3 acetylation at the E2F1 response elements within the MCM7 promoter. Human coronary artery SMCs were treated as Figure 5C . Chromatin immunoprecipitation (ChIP) was performed using an antibody against acetylated Histone H3 (Lys9). Quantification of immunoprecipitated chromatin was performed by real-time PCR using primers covering E2F1 binding sites within the promoters of MCM7. Data are presented as mean±SEM (#P<0.05 vs quiescent, *P<0.05 vs shCTL). D and E, TERT deficiency decreases acetylation of histone H3. Vascular SMC from G1TERT +/+ and G1TERT −/− mice were stimulated with FBS after 24 hour serum-free starvation, and protein was harvested. Western blotting was performed using antibody against acetylated Histone H3 (Lys9). Histone H3 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as loading controls. Densitometric quantification (E) normalized to H3. Data are presented as mean±SEM (#P<0.05 vs quiescent, *P<0.05 vs G1TERT +/+ ). F, Interaction of TERT and CREBbinding protein (CBP) in human coronary artery SMC. Immunoprecipitation (IP) of TERT from cell lysates followed by Western blotting (WB) with anti-CBP. The same blot was subsequently stripped and reprobed with anti-TERT antibody. G, TERT depletion reduces CBP recruitment to the E2F1 response element in the MCM7 promoter. Human coronary artery SMC were treated as in Figure 5C . ChIP was performed using anti-CBP antibody. Quantification of immunoprecipitated chromatin was performed by real-time PCR using primers covering E2F1 binding sites within the MCM7 promoter. Data are presented as mean±SEM (#P<0.05 vs quiescent, *P<0.05 vs shCTL). H-J, The proliferative defect induced by TERT deletion is not reversed by overexpression of E2F1. Vascular SMC from G1TERT +/+ and G1TERT −/− mice were transduced with 25 plaque-forming units (PFU)/cell adenovirus overexpressing E2F1 or control GFP. MCM7 mRNA expression was analyzed by real-time RT-PCR after 24 hours (H). Cell proliferation was analyzed after 24 hours by cell counting using a hemocytometer (I) or by 5-bromo-2′-deoxyuridine (BrdU) incorporation (J). Data are presented as mean±SEM (#P<0.05 vs Adx-GFP, *P<0.05 vs G1TERT +/+ ).
